How to Help Your Patients Find Mifepristone In Stock: A Provider's Guide

Writing the prescription is just the beginning. For many mifepristone patients in 2026, the harder challenge is actually getting the prescription filled. REMS certification requirements, limited pharmacy participation, state laws, and legal uncertainty all create barriers between your patient and their medication. This guide provides concrete, practical workflows to help your clinical team support patients through every step of the mifepristone access process.

Step 1: Know Your Local Certified Pharmacy Landscape

The most impactful thing your practice can do is maintain an up-to-date list of REMS-certified pharmacies in your service area. Research from USC Schaeffer shows that in states where telehealth is permitted, in-store pharmacies account for less than 2% of mifepristone fills — but those pharmacies exist, and knowing which ones they are can save your patients significant frustration. Call pharmacies in your area quarterly and ask: "Are you certified under the Mifepristone REMS Program and currently dispensing mifepristone?" Document the answers and share with your care coordination team.

Alternatively, use medfinder for providers to offload this research. medfinder calls pharmacies in your patient's area and identifies which ones can fill the specific prescription — eliminating the need for your staff or your patient to make those calls.

Step 2: Integrate Telehealth + Mail-Order Into Your Workflow

In states where abortion is legal and telehealth prescribing is permitted, mail-order dispensing through telehealth-affiliated pharmacies is the dominant access channel. As of June 2026, this route is preserved under the Supreme Court's stay. If your practice operates a telehealth service, ensure your mail-order pharmacy partner is REMS-certified and has reliable shipping turnaround times (typically 2-5 business days after prescription confirmation). Communicate expected delivery timelines clearly to patients.

For practices that provide in-person care, keeping mifepristone on-site and dispensing it directly — rather than sending patients to retail pharmacies — is an approach used by reproductive health clinics and Planned Parenthood. Dispensing directly to the patient at the time of the visit eliminates the pharmacy access barrier entirely. If your practice is not set up for on-site dispensing, consider whether this is feasible to implement given your patient population's access challenges.

Step 3: Prepare Patients for the Patient Agreement Form Process

One common source of delays is the Patient Agreement Form required under the REMS. Patients must review, discuss, and sign this form before mifepristone can be dispensed. For telehealth patients, this is typically completed digitally before the appointment. For in-person patients, complete this as part of the clinical visit — do not assume the pharmacy will handle it. The form covers: understanding of the medication, gestational age limits, risk of ectopic pregnancy, signs of serious complications, and follow-up expectations. Building a brief patient education workflow around this form — ideally with written materials in your patient's primary language — will reduce confusion and ensure REMS compliance.

Step 4: Address Cost and Insurance Barriers Proactively

Cost is a meaningful barrier for many patients. Without insurance coverage, mifepristone for abortion costs $300-$800 at an in-person clinic and $50-$200 via telehealth. With insurance, cost-sharing can bring this to as low as $5-$30 — but coverage varies widely by state and plan. For Korlym (Cushing's), the medication is prohibitively expensive without insurance, making prior authorization a mandatory first step. Build the following into your intake workflow for mifepristone patients:

• Verify insurance coverage and prior authorization requirements before the patient leaves the clinic or ends the telehealth visit.
• For uninsured or underinsured abortion patients, connect them with the National Abortion Federation Hotline Fund (1-800-772-9100), local abortion funds, or Planned Parenthood's sliding scale fee structure.
• For Korlym patients, refer to Corcept Therapeutics' patient assistance program, which may be available for patients who meet income criteria.

Step 5: Have a Clear Plan for Access Failures

Even with good preparation, some patients will encounter barriers. Build a "plan B" into your clinical protocol:

1. If the local pharmacy is not REMS-certified: Direct to a telehealth mail-order service or known certified pharmacy, or dispense from your clinic if applicable.
2. If the patient's state has restrictive laws: Discuss traveling to an abortion-legal state if feasible, and connect with abortion travel fund resources.
3. If the patient cannot access mifepristone at all: Discuss the misoprostol-only alternative (endorsed by WHO and ACOG), or surgical abortion if gestational age and patient preference align.

Staying Current: Monitoring REMS and Legal Changes

The mifepristone regulatory environment is changing faster than most clinical areas. Prescribers should: (1) Subscribe to FDA MedWatch email updates on mifepristone, (2) Monitor ACOG Practice Advisories for updated clinical guidance, (3) Consult institutional legal counsel on state law developments specific to your practice location, and (4) Review the mifepristonerems.com website quarterly for REMS updates. The FDA safety review of mifepristone's REMS, which began in September 2025, is still ongoing — results from this review will be significant for prescribing practice.

How medfinder Supports Provider Workflows

Care coordinators and clinical staff spend significant time calling pharmacies to locate medications for patients. medfinder for providers automates this process: your staff or patient submits the medication and location, and medfinder identifies which pharmacies can fill the prescription. This is particularly valuable for mifepristone, where the pharmacy landscape is fragmented and certification status is not publicly indexed. For more on the regulatory context, see our provider regulatory update for 2026.